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Abstract. The present study sought to determine the survival
outcomes for women diagnosed with breast and endometrial
cancer. Using SEER data, a population‑based cohort study
of women diagnosed with breast and endometrial cancer
was conducted. Kaplan‑Meier survival curves were created
for disease‑specific survival rates. A total of 2,027 women
diagnosed with breast and endometrial cancer were identified. Of these, 1,296 (63.9%) developed breast cancer first
and 731 (36.1%) developed endometrial cancer first. Regional
lymph node involvement was significantly more common with
a breast cancer diagnosis [522 (25.8%) women] compared
with an endometrial cancer diagnosis [87 (4.3%) women]
(P<0.05). Factors associated with decreased survival included
a high tumor grade in endometrial cancer, nodal positivity
and estrogen receptor‑negative breast cancer (P<0.05 for
each). There were 83 (4.1%) mortalities due to breast cancer,
63 (3.1%) mortalities due to endometrial cancer and 178 (8.8%)
mortalities due to other causes (P<0.05). In conclusion, for
women diagnosed with breast and endometrial cancer, the
cumulative risk of mortality at five years following the second
cancer diagnosis is nearly four times more likely to be due to
breast cancer than endometrial cancer.
Introduction
Breast cancer is the most common type of cancer diagnosed
in women in the United States (US) (1). Cancer of the endometrium is the fourth most common cancer diagnosis in US
women, following cancers of the lung and bronchus and the
colon and rectum (1). Breast cancer is the second most common
cause of cancer mortality in US women, following mortalities
due to lung and bronchial cancers; endometrial cancers are
eighth on the list of mortalities due to cancer in US women (1).
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The American Cancer Society has estimated that there were
226,870 new cases of invasive breast cancer and 63,300 new
cases of in situ breast cancer in the year 2012 (1). The lifetime
risk for a diagnosis of breast cancer based on the 2006‑2008 rates
was reported at 12.29% (2). The Surveillance, Epidemiology
and End Results (SEER) database reported the median age of
diagnosis of breast cancer during 2004‑2008 as 61 years old,
while the median age of mortality due to breast cancer was
68 years old (2). The age‑adjusted incidence rate during the
same time frame was 124.0/100,000 women/year, while the
age adjusted mortality rate was 23.5/100,000 women/year (2).
The five‑year relative survival for 2001‑2007 in the SEER
group was 89.1%. When adjusted by stage, the SEER reported
a five‑year relative survival of 98.6% for those with locally
confined disease, 83.8% for those with regional lymph node
disease and 23.3% for those with metastatic disease (2).
The American Cancer Society has estimated that there were
47,130 new cases of endometrial cancer in the year 2012 (1).
The lifetime risk for a diagnosis of endometrial cancer based
on the 2006‑2008 rates was reported at 2.61% (3). The SEER
database reported the median age of diagnosis of endometrial
cancer during 2004‑2008 as 61 years old, while the median
age of mortality due to endometrial cancer was 72 years
old (3). The age adjusted incidence rate during the same time
frame was 23.9/100,000 women/year, while the age adjusted
mortality rate was 4.2/100,000 women/year (3). The five‑year
relative survival for 2001‑2007 in the SEER group was 81.8%.
When adjusted by stage, the SEER reported a five‑year relative survival of 95.8% for those with locally confined disease,
67.0% for those with regional lymph node disease and 15.9%
for those with metastatic disease (3).
The overall survival outcomes of women who have been
diagnosed with breast and endometrial cancer have not previously been reported in the literature. To that end, the present
study investigated the survival data with regard to patients
diagnosed with synchronous or metachronous breast and
endometrial cancer, utilizing SEER data.
Materials and methods
The present study was a retrospective, population‑based
cohort study of women with a primary diagnosis of invasive
breast cancer plus a primary diagnosis of endometrial adenocarcinoma. The SEER program database was utilized to
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gather the study patients. The patients included in the study
were diagnosed between January 1, 1988 and December 31,
2007. All study patients were recorded in the SEER database
as not having evidence of distant metastases at the time of
diagnosis. Additionally, all study patients had been followed
up for at least one after the second cancer diagnosis was
recorded.
The sequence of diagnosis of tumor type was recorded.
The status at the end of the study was recorded as alive, breast
cancer‑related mortality, endometrial cancer‑related mortality
or mortality due to other causes. The histological grades were
recorded as well‑differentiated (grade I), moderately‑differentiated (grade II), poorly‑differentiated (grades III‑IV) or
unknown. The pathological lymph node status was recorded
as negative, positive or unknown. The breast cancer receptor
status for the estrogen receptor (ER) and the progesterone
receptor (PR) was recorded as positive, negative or unknown.
The age at the time of the second tumor diagnosis was
recorded in years and the time between the first and second
tumor diagnoses was recorded in months.
The endpoints for this study were breast cancer‑specific
mortality and endometrial cancer‑specific mortality. These
endpoints were recorded using the cause of mortality and the
total completed months of follow‑up noted in the SEER database.
A comparative risk regression analysis was used to
analyze the risk of mortality secondary to breast cancer or
endometrial cancer with regard to the tumor type at first
diagnosis, the lymph node status, the histological differentiation of the two tumor types and the hormone receptor status.
This analysis was dichotomized into an early follow‑up
period (<2.5 years) and a late follow‑up period (2.5‑5 years)
to account for a survival crossover observed in the cumulative
risk analysis. A cause‑specific cumulative risk analysis was
performed in the analysis of the risk of mortality with regard
to the order of the tumor type diagnosis. All analyses utilized
a null hypothesis rejection with a P‑value of <0.05. All statistical analyses were performed using R version 2.13.0 of the
cmprsk package (4).
Results
Patients and demographics. Using the SEER database, a total
of 2,027 women who had a primary diagnosis of invasive
breast cancer plus a primary diagnosis of endometrioid‑type
endometrial cancer were identified during the period of
1998‑2007. Table I provides a summary of the patient and
tumor characteristics that were utilized for the present study.
During the study period, 1,296 women (63.9%) were identified with an initial cancer diagnosis of invasive breast cancer.
The remaining 731 (36.1%) were women with an initial cancer
diagnosis of endometrial cancer or those who had endometrial
cancer diagnosed synchronously with their breast cancer. The
median age at the time of the diagnosis of the second cancer
was 68 years old. The median time measured between the
initial diagnosis of cancer and the diagnosis of the second
cancer type was 45 months. At the end of the study period,
1,703 women (84.0%) were still living, while 324 women (16%)
had succumbed to various causes. The cause of mortality
recorded in the SEER database was attributed to breast cancer
in 83 women (4.1%), to endometrial cancer in 63 women (3.1%)

Table I. Summary of characteristics of interest for 2,027 women
diagnosed with breast and endometrial carcinoma.
Characteristic
First tumor diagnosis, n (%)
Breast cancer
Endometrial cancer/synchronous
Status at end of study, n (%)
Alive
Breast mortality
Endometrial mortality
Other mortality
Endometrium histological grade, n (%)
Well‑differentiated (SEER grade I)
Moderately‑differentiated (SEER grade II)
Poorly‑differentiated (SEER grades III‑IV)
Unknown
Breast histological grade, n (%)
Well‑differentiated (SEER grade I)
Moderately‑differentiated (SEER grade II)
Poorly‑differentiated (SEER grades III‑IV)
Unknown
Endometrium lymph node status, n (%)
Negative
Positive
Unknown
Breast lymph node status, n (%)
Negative
Positive
Unknown
Breast ER status, n (%)
Negative
Positive
Unknown
Breast PR status, n (%)
Negative
Positive
Unknown
Median age at second tumor diagnosis,
years (interquartile range)
Median time between first and second
tumors, months (interquartile range)

Value
1296 (63.9)
731 (36.1)
1703 (84.0)
83 (4.1)
63 (3.1)
178 (8.8)
913 (45.0)
643 (31.7)
316 (15.6)
155 (7.6)
394 (19.4)
813 (40.1)
641 (31.6)
179 (8.8)
980 (48.3)
87 (4.3)
960 (47.4)
1263 (62.3)
522 (25.8)
242 (11.9)
323 (15.9)
1364 (67.3)
340 (16.8)
466 (23.0)
1178 (58.1)
383 (18.9)
68 (60‑76)
45 (17‑81)

SEER, Surveillance, Epidemiology and End Results; ER, estrogen
receptor; PR, progesterone receptor.

and to other causes not associated with breast or endometrial
cancer in 178 women (8.8%).
The tumor characteristics shown in Table I demonstrate
that cancers of the endometrium were more likely to be of a
lower histological grade at the time of diagnosis. Endometrial
cancers were observed to be histologically well‑differentiated
in 913 of patients (45.0%), moderately‑differentiated in 643 of
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Figure 1. Cause‑specific cumulative risk of mortality for 2,027 women diagnosed with breast and endometrial cancer.

patients (31.7%) and poorly‑differentiated in 316 of patients
(15.6%). This was compared with the findings in the breast
tumors, which were histologically well‑differentiated in 394 of
patients (19.4%), moderately‑differentiated in 813 of patients
(40.1%) and poorly‑differentiated in 641 of patients (31.6%).
The histological grade could not be determined from the SEER
database in 155 (7.6%) of patients with endometrial tumors and
in 179 (8.8%) of patients with breast tumors. The lymph node
status at the time of diagnosis was less likely to be known for
the endometrial tumors, although when it was known, it was
positive for disease in only 87 (4.3%) of patients and negative
in 980 (48.3%) of patients. The lymph node disease burden
in breast cancer was noted to be negative in 1,263 (62.3%) of
patients and positive in 522 (25.8%) of patients. The hormone
receptor status of the breast tumors revealed that the tumors
were more likely to be positive rather than negative for ER
and PR. The ER status was negative in 323 (15.9%) of tumors,
positive in 1,364 (67.3%) of tumors and unidentifiable in 340
(16.8%) of tumors. The PR status was negative in 466 (23.0%)
of tumors, positive in 1,178 (58.1%) of tumors and unidentifiable in 383 (18.9%) of tumors.
Mortality risk analyses. The results of the analysis of the
cause‑specific cumulative risks of mortality are shown in
Fig. 1. The greatest risk of mortality, independent of which
tumor type was identified at the primary diagnosis, was attributed to factors other than breast or endometrial cancer. The
risk of breast cancer being the cause of mortality was similar
regardless of whether the patients were initially diagnosed
with breast or endometrial cancer. The risk of mortality
attributed to endometrial cancer was also similar to the risk
of succumbing to breast cancer at the five‑year time‑point, if
the tumor at the initial diagnosis was breast cancer. The risk
of mortality attributed to endometrial cancer, if the tumor at
the initial diagnosis was endometrial cancer, was lowest at the
five‑year time‑point when compared with other causes.
The regression analyses of the comparative risk of endometrial cancer or breast cancer mortalities as associated with
various factors are summarized in Fig. 2. The analysis was
performed using two time periods in the study; the study time

was divided at the 2.5‑year mark. This was established due to
the dichotomy of the endometrial cancer mortality cumulative
risk lines observed in Fig. 1. The lines deviated from each
other in the first half of the study, but became parallel in the
second half.
Prognostic factors. As expected, in the two halves of the
study, positive lymph node disease was associated with an
increased risk of mortality of the respective cancer type. The
positive burden of breast cancer in the lymph nodes increased
the risk of mortality from breast cancer in the first [Hazard
ratio (HR), 2.71) and second half (HR, 3.84) of the study. The
positive burden of endometrial cancer in the lymph nodes
increased the risk of mortality from endometrial cancer in
the first (HR, 4.99) and second half (HR, 7.21) of the study.
The presence of lymph nodes with an endometrial cancer
burden was also associated with a significant increase in the
risk of mortality due to breast cancer in the second half of
the study compared with the first half of the study (HR, 2.05
and HR, 4.57, respectively). The histological grade of breast
cancer, when adjusted for other factors, did not have a significant association with breast cancer mortalities. Endometrial
cancer mortalities did show an increased association with a
poorly‑differentiated tumor status upon histological examination when compared with the well‑differentiated tumors.
This effect was more significant in the first half of the study
period compared with the second half (HR, 17.39 and 8.31,
respectively). The risk of mortality from endometrial cancer
was also observed to have a significant association with the
differentiation level of the breast tumor. In the first half of
the study, breast tumors with moderate or poor differentiation were associated with an increased risk of mortality
from endometrial cancer (HR, 4.46 and 3.29, respectively).
Conversely, in the second half of the study breast tumors with
poor differentiation were associated with a decreased risk
of mortality from endometrial cancer (HR, 0.12). The only
association of significance with regard to hormone receptor
status was identified in the first half of the study, whereby a
negative ER status in a breast tumor was associated with an
increased risk of mortality due to breast cancer (HR, 2.89).
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Figure 2. Regression analysis for risk of mortality for 2,027 women diagnosed with breast and endometrial cancer as adjusted for tumor‑specific factors. The
first half of the study period is represented by solid bars and the second half of the study is represented by broken bars. Hazard ratios (HR; 95% CI). Adjusted:
age at second tumor, time between tumors. Not shown: comparisons with unknown.

Discussion
Breast cancer is the most commonly diagnosed cancer in
women in the US and endometrial cancer is the fourth most
common cancer diagnosis (1). The present study investigated
the impact of a synchronous or metachronous diagnosis of
invasive breast and endometrial cancer on survival outcomes.
This appears to be the first study of survival outcomes as
impacted by these two types of cancer. The present study was
an observational study of 2,027 women identified from the
SEER database as having a diagnosis of both types of cancer.
The results of this study may aid clinicians in treating patients
diagnosed with both types of cancer.
The association of endometrial cancer following the
treatment of a previously diagnosed breast cancer has been
established in the literature, specifically with regard to the use
of tamoxifen in the adjuvant treatment of breast cancer (5,6).
The various types of endometrial cancer that develop in
women during and after tamoxifen therapy have been previously studied in the literature (5,6). Women were observed to
be more likely to develop a high‑grade or high‑risk type of
endometrial cancer (type II) when the diagnosis was established following the cessation of tamoxifen. Bland et al (7)
noted this difference after a six‑month time frame from the
completion of therapy and Ferguson et al (8) noted it after a
12‑month period between tamoxifen therapy discontinuation
and endometrial cancer diagnosis. It has also been observed
that there is an increased risk of these high‑risk subtypes of
endometrial cancer in women who complete the standard
five‑year course of tamoxifen therapy compared with those
are administered it for <5 years (7). The present study specifi-

cally investigated the endometrioid variant of endometrial
cancer, which is classified as a type I endometrial tumor in the
majority of cases, although if it is of a high histological grade it
may be classified as a type II tumor. We were unable to discern
with certainty whether any cases of endometrial cancer in the
present patients were due to tamoxifen therapy, as this variable was not recorded in the SEER dataset. There were 1,296
(63.9%) women who were diagnosed with breast cancer first
and 67.3% of the breast tumors in the study were ER‑positive.
There was a median of 45 months and an interquartile range
of 17‑81 months between the diagnoses of the first and second
tumors. We would infer from this data that a significant
percentage of these patients were likely offered endocrine
therapy as adjuvant treatment for their breast cancer, but we
are unable to determine whether tamoxifen was utilized,
versus an aromatase inhibitor, or whether there was a causal
relationship with the patients' subsequent endometrial cancer.
In the present study, the risk of mortality due to other
causes was greater than the risk of mortality from either
breast or endometrial cancer. This finding of ‘other cause’
mortality has been documented in previous literature for
breast cancer, but the data is unclear on this matter for endometrial cancer (9). In the present analysis, it was shown that
the risk of mortality from breast cancer was similar regardless of which tumor type was diagnosed initially. By contrast,
the risk of mortality from endometrial cancer was markedly
lower if the initial diagnosis was endometrial cancer. This
may also be related to the fact that patients whose first diagnosis was breast cancer would likely have received tamoxifen
and subsequently were at risk of developing a higher grade of
endometrial cancer, as opposed to those whose initial diag-
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nosis of endometrial cancer was more likely to be of a lower
tumor grade (10,11).
There were a number of unexpected outcomes from the
present analysis. As expected, the patients with the higher
histological grades of endometrial cancer were more likely
to succumb to endometrial cancer. However, this effect was
not observed in the analyses of histological grades and breast
cancer‑specific survival. Although the histological grade of
breast tumors has been shown to be correlated with a poorer
prognosis in previous studies (12‑14), the present study did not
observe any significant effect on the risk of mortality from
breast cancer based on the increasing histological grade. There
was an unexpected effect of the breast tumor histological
grade on the risk of mortality from endometrial cancer. In the
present study, patients who had high‑grade breast tumors were
at an increased risk of mortality due to endometrial cancers
in the first half of the study. This effect was not observed in
the second half of the study. The clinical significance of this
finding is unclear. It may be a reflection of the shorter interval
between the two cancer diagnoses and the more aggressive
biology of the endometrial cancer.
As expected, as lymph node burden increases for a specific
cancer, there is a concomitantly increased risk of mortality
from that specific disease. An unexpected finding was observed
in the later stage of the study, where the lymph node burden
of endometrial cancer showed significance in an increased
association with mortality due to breast cancer. There was also
an increased risk of mortality due to endometrial cancer with a
positive lymph node burden of breast cancer in the second half
of the study, although this association was not at a statistically
significant level. Although these correlations between lymph
node disease and mortality due to the opposing cancer type
were of statistical interest in the present analyses, it is unclear
whether there is a clinical link between the two histologies that
would result in this finding.
There are a number of limitations to the present study that
are derived from its nature as a retrospective cohort study.
The primary outcome that was assessed was cancer‑specific
mortality, but the comparison only included patients with a
diagnosis of both cancer types. A helpful addition would be the
comparison of this group with patients with a diagnosis of breast
or endometrial cancer only. There are also limitations associated with the use of the SEER database and the information
available for analysis. The addition of information with regard to
the comorbidities, the margin status of tumor resections and the
adjuvant treatments are important variables that were not available in the present analysis of this specific group of patients. The
majority of patients did not have lymph node disease and there
was a large volume of patients with unknown lymph node status
in the endometrial cancer group. The results of the analysis may
be different if a group of patients with a larger burden of disease
at diagnosis was examined. Despite these limitations, the SEER
database is a large population database that is used frequently in
epidemiological studies (15).
The present study provides the first mortality analysis of
patients with either synchronous or metachronous breast and
endometrial cancer, two commonly diagnosed cancers among
women in the US. These findings should be considered when
clinicians enter discussions concerning prognoses with patients
of similar standing. It is important to encourage patients to
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continue surveillance for a second type of cancer even after
they have been diagnosed with a primary type of cancer. It is
equally important for clinicians to continue screening practices
for other cancers for patients who have been treated for another
cancer diagnosis. For example, women who have been diagnosed
with endometrial cancer should be encouraged to continue to
undergo annual screening mammography. Furthermore, it is
of particular importance for clinicians to educate patients who
have been treated with adjuvant tamoxifen for breast cancer on
the signs and symptoms of endometrial cancer and the necessity
of reporting these signs and symptoms to their physician in a
timely manner so that diagnostic interventions may be utilized.
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